Behavior of Lp(a) and apoproteins (A1, B, C2, C3, E) during and after therapy with simvastatin

This publication has 22 references indexed in Scilit:

• Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
  JAMA, 1993
• Proliferation of Human Smooth Muscle Cells Promoted by Lipoprotein(a)
  Science, 1993
• A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition
  Metabolism, 1992
• The Mysteries Of Lipoprotein(a)
  Science, 1989
• 'Lp(a)' Joins Other Serum Cholesterol Lipoproteins as Risk Determinant
  JAMA, 1989
• HMG-CoA Reductase Inhibitors for Treatment of Hypercholesterolemia
  New England Journal of Medicine, 1988
• Simvastatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolaemia
  Atherosclerosis, 1988
• The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosisDependence on serum LDL levels
  Atherosclerosis, 1986
• EFFECTS OF SYNVINOLIN (MK-733) ON PLASMA LIPIDS IN FAMILIAL HYPERCHOLESTEROLAEMIA
  The Lancet, 1986
• Lowering Blood Cholesterol to Prevent Heart Disease
  JAMA, 1985